Agenus Inc - Company Profile
Powered by 
All the data and insights you need on Agenus Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Agenus Inc Strategy Report
- Understand Agenus Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Agenus Inc (Agenus), formerly, Antigenics Inc, is a clinical-stage biotechnology company specializing in the discovery and development of therapies that use the body's immune system to fight cancer and infections. The company develops an array of immune checkpoint antibodies, adoptive cell therapies, and neoantigen vaccines.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Agenus' research and development efforts entail the careful controlled use of potentially dangerous substances, chemicals, biological materials, different radioactive compounds, and for some experiments, recombinant DNA. The company is certain that its practices meet the requirements set forth by local, state, and federal authorities, the possibility of harm or unintentional contamination cannot be entirely eliminated. It carries out its operations in accordance with the National Institutes of Health Guidelines for Recombinant DNA Research. The company has leased its main research and development, manufacturing and corporate offices occupying about 82,000 square feet in Lexington, Massachusetts. The company incurred US$186.7 million on its R&D activities in FY2022, which grew 4.5% YoY.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer